46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany

1 May 2011. Related: Conference reports, Conference index, EASL 46 Berlin 2011.

The development of compounds that directly target hepatitis C virus (direct acting antivirals or DAA’s), used with and without pegylated interferon (PEG-IFN) and ribavirin is moving rapidly and with a burgeoning pipeline.

The following report is an edited summary of a rapid summary from Jules Levin whose natap.org website posted numerous studies from this meeting.

• Rapid report: state of HCV policy, treatment, access

Abstracts from the oral and poster sessions are available online at the following links:

http://www1.easl.eu/easl2011/program/Orals/

http://www1.easl.eu/easl2011/program/Posters/

A limited number of web casts are due to be posted online but were not yet available when HTB went to press.